Industry · Exploratory
Quantum Computing for Biotechnology and Genomics
Biotechnology and genomics produce vast data sets and ask hard structural and chemical questions. Quantum computing could help with enzyme and protein chemistry in the long term, while genome analysis is mainly a data problem where classical methods are far ahead.
Maturity
Exploratory; enzyme chemistry is the strongest case, genomics the weakest
Most credible quantum workload
Electronic structure of enzyme active sites and metal-binding proteins
Hardware needed
Fault-tolerant machines with thousands of logical qubits
Strongest classical competition
AlphaFold-class models, molecular dynamics, indexing tools such as BWA, and GPU genomics pipelines
Notable work
Moderna and IBM on mRNA structure; academic studies on genome assembly and protein folding on quantum hardware
Realistic horizon
2030s for enzyme chemistry; genomics advantage uncertain
Overview
Biotechnology applies biology to make medicines, materials, fuels, and food ingredients, and genomics reads and interprets the genetic code that underlies all of it. Both fields are driven by data and by molecular structure. Sequencing machines produce billions of short reads, and the human genome alone contains about 3.1 billion base pairs. Predicting how a protein folds or how an enzyme works is a structural and chemical problem that has resisted exact computation for decades.
AI has transformed part of this landscape: AlphaFold's protein structure predictions won the 2024 Nobel Prize in Chemistry. That success narrows what quantum computing might add, and it also sharpens the question. The remaining hard problems are those that depend on electron-level chemistry, such as enzyme mechanisms and metal-binding sites, and for those a quantum computer could in principle help. Genomics data analysis, by contrast, is dominated by data volume, a problem for which quantum computers are poorly suited.
Why this industry is a candidate for quantum computing
Enzymes catalyze reactions through intricate electronic rearrangements at their active sites. Understanding and engineering them, for example to produce a chemical sustainably or to degrade plastics, requires modeling those rearrangements accurately. The same fault-tolerant quantum simulation that is proposed for industrial catalysts applies, and nitrogenase and cytochrome P450 are standard benchmark cases.
Genomics and bioinformatics problems such as assembly, alignment, and variant calling are string and graph problems on huge data sets. Quantum algorithms such as Grover search offer quadratic speedups in principle, but loading data and the efficiency of classical tools built on clever indexing remove the advantage. Researchers have formulated these tasks for quantum annealers and variational circuits, mostly as demonstrations.
Key facts and numbers
| Item | Detail |
|---|---|
| Human genome size | About 3.1 billion base pairs |
| Sequencing read length | Short-read platforms commonly produce reads of about 150 bases |
| AlphaFold recognition | 2024 Nobel Prize in Chemistry to Hassabis, Jumper, and Baker for protein structure prediction and design |
| Quantum protein folding demonstration | Researchers folded a seven-amino-acid peptide on an IBM quantum device in 2021, a toy-scale result |
| Quantum genome assembly studies | Formulated as optimization and tested on quantum and quantum-inspired annealers for small genomes and read sets |
| Enzyme benchmarks | Nitrogenase FeMoco and cytochrome P450 resource estimates are in the millions of physical qubits |
Where quantum computing could help
Enzyme mechanisms and protein active sites
The problem: Designing or improving enzymes requires accurate models of how electrons move during catalysis, particularly for metal-containing active sites where approximate methods disagree.
The quantum approach: Fault-tolerant quantum phase estimation to compute active-space energies, combined with classical molecular dynamics for the protein environment.
Where things stand: Resource estimates exist for key enzymes, and small fragments have been run on hardware. AI-based design tools handle structure and sequence well, and electronic accuracy is the gap that quantum methods target.
Related algorithms: Quantum Phase Estimation (QPE), Variational Quantum Eigensolver (VQE), Linear Combination of Unitaries (LCU)
Protein folding and design
The problem: Predicting the three-dimensional shape of a protein from its sequence, and designing sequences that fold into desired shapes, are central to biotechnology.
The quantum approach: Lattice models of folding are mapped to optimization problems for quantum annealers and variational circuits.
Where things stand: Quantum demonstrations handle peptides with a handful of residues, which is far from real proteins, while AlphaFold and related AI models solve the structure prediction problem at scale. Quantum optimization for folding has no advantage over classical approaches so far.
Related algorithms: Quantum Approximate Optimization Algorithm (QAOA), Quantum Annealing, Variational Quantum Eigensolver (VQE)
Genome assembly, alignment, and variant analysis
The problem: Reconstructing genomes from short reads, aligning sequences, and identifying variants involve searching and optimizing over huge sets of strings.
The quantum approach: Researchers have formulated assembly as a traveling-salesman-like optimization for annealers, and studied quantum search for sequence matching.
Where things stand: Demonstrations use very small read sets. Classical tools using compressed indexes, such as the Burrows-Wheeler transform, are extremely fast, and data loading removes the advantage of quantum search, so genomics is a research direction and not a near-term application.
Related algorithms: Grover's Algorithm, Quantum Annealing, Quantum Approaches to the Traveling Salesman Problem
Synthetic biology and metabolic engineering
The problem: Engineering microbes to produce chemicals requires optimizing metabolic pathways, gene expression, and growth conditions, and predicting enzyme behavior.
The quantum approach: Pathway design and flux analysis are optimization problems, and enzyme design uses chemistry simulation. Quantum linear programming and annealing have been proposed for the former.
Where things stand: These approaches are theoretical or use small models. Classical flux balance analysis and machine learning are mature, and quantum contributions would be through chemistry in the long term.
Related algorithms: Quantum Algorithms for Semidefinite Programming, Quantum Approximate Optimization Algorithm (QAOA), Variational Quantum Eigensolver (VQE)
Who is working on it
- Moderna and IBM, which have explored hybrid quantum workflows for predicting the secondary structure of mRNA.
- Academic groups and national laboratories studying genome assembly, protein folding, and enzyme chemistry on quantum devices.
- The Novo Nordisk Foundation Quantum Computing Programme in Denmark, which funds quantum research relevant to biology and chemistry.
- Startups and software firms such as ProteinQure, Quantinuum, and Phasecraft, which develop chemistry and life-science tools.
- Sequencing and bioinformatics companies that follow quantum developments while investing mostly in classical and GPU pipelines.
Realistic timeline
| Horizon | What to expect |
|---|---|
| Now to 2028 | Small demonstrations in folding, assembly, and mRNA structure. AI continues to dominate structure prediction and design. |
| 2028 to 2032 | Early fault-tolerant machines might treat small enzyme active spaces beyond exact classical methods. |
| 2032 and later | If large machines arrive, enzyme and metalloprotein simulation could guide engineering. Genomics advantage remains doubtful. |
How to judge quantum claims in this sector
Biology claims need particular care because the gap between a toy demonstration and a useful application is wide. A quantum computer that folds a seven-residue peptide on a lattice has shown that an optimization can be encoded, not that it can fold proteins. When assessing such results, ask about the size of the molecule, the physical realism of the model, and how it compares with AI predictions and molecular dynamics.
For genomics, the key is data. Any claimed speedup should state how the data are loaded and what the classical baseline is. Since genome analysis pipelines already run on optimized indexes and GPUs, a credible quantum advantage would need to overcome both the loading cost and a very strong baseline, which no current proposal has done.
What stands in the way
- Scale: real proteins and enzymes need far more qubits than current devices provide.
- Data loading: genomic data sets are huge and hard to encode in quantum states.
- Classical progress: AlphaFold-class models and GPU genomics pipelines keep improving.
- Experimental validation: computational predictions must be confirmed in the lab, which is slow and costly.
What organizations in this sector should do now
- Use AI and classical tools for structure and sequence analysis now, and define the electronic-structure questions that remain unsolved.
- Collaborate with academic groups on enzyme and metalloprotein benchmarks.
- Be skeptical of genomics claims that omit data loading and strong classical baselines.
- Follow the chemistry resource-estimate literature to understand when hardware could matter.
Myths versus reality
- Myth: quantum computers will decode genomes faster. Reality: genomics is limited by data and well served by classical tools.
- Myth: AlphaFold made quantum computing irrelevant to biology. Reality: it solved structure prediction, and electron-level chemistry remains a separate challenge.
- Myth: quantum protein folding is solved. Reality: demonstrations use peptides of a few residues.
The bottom line
Quantum computing's best prospect in biotechnology is the chemistry of enzymes and metal-binding proteins, a long-term goal that depends on fault-tolerant hardware. Genomics and structure prediction are well served by classical and AI methods, and claims of quantum advantage there should be treated with caution.
Frequently asked questions
Can quantum computers fold proteins?
Only toy peptides so far. AI models such as AlphaFold already predict protein structures at scale, and quantum methods have not matched them.
Will quantum computers speed up genome sequencing?
Sequencing is a measurement technology. For analysis, classical tools are highly efficient, and data loading limits quantum speedups.
Where could quantum computing help biotechnology?
In accurate simulation of enzyme active sites and metal-containing proteins, which are hard for classical approximations, once fault-tolerant machines exist.
What did Moderna and IBM do?
They explored hybrid quantum-classical methods for predicting mRNA secondary structure, on sequences short enough for current devices. The work is exploratory.
How is this different from pharmaceuticals?
Pharmaceuticals focus on drug candidates, binding, and metabolism, while biotechnology and genomics cover proteins, enzymes, genomes, and engineered organisms. Both rely on molecular simulation.
Keep exploring
- Algorithm: Quantum Phase Estimation (QPE)
- Algorithm: Variational Quantum Eigensolver (VQE)
- Algorithm: Quantum Annealing
- Algorithm: Grover's Algorithm
- Hardware: IBM Heron (r1, r2, and r3)
- Hardware: Quantinuum H2
- Company: IBM
- Company: Quantinuum
- Company: Phasecraft
- Research: Higher-Accuracy Molecular Energy Estimation Using Adaptive VQE Ansätze
- Research: Automated Active Space Selection Improves Practical VQE Chemistry Simulations
- Industry: Quantum Computing for Pharmaceuticals and Drug Discovery
- Industry: Quantum Computing for Healthcare
- Industry: Quantum Computing for Agriculture and Food
- Industry: Quantum Computing for the Chemical Industry
This page is written for educational purposes and summarizes public announcements, published research, and published resource estimates (last reviewed September 30, 2026). Vendor and customer claims have not all been independently verified, timelines are estimates, and nothing here is investment or business advice.